Stymied by an FDA rejection last year, Ionis and Akcea’s ultrarare lipid disorder treatment Waylivra seemed doomed, at least for now. Fortunately, the drug found new life in Europe. More: Rejected by the FDA, Ionis and Akcea's Waylivra finds new
read moreNovartis’ newly approved multiple sclerosis therapy Mayzent has already shown an ability to cut disability progression and forestall brain shrinkage in patients with the secondary progressive form of the disease. Now, an analysis shows it aids cognition, too. More: Novartis'
read moreThe authorisation follows the positive opinion recommending approval provided by the Committee for Medicinal Products for Human Use (CHMP). More: Waylivra granted conditional marketing authorisation in Europe Source: News
read moreThe disease that causes one-third of all AMR related deaths – drug-resistant tuberculosis (DR-TB) – is rarely talked about. More: AMR could cause 10 million deaths per year by 2050 Source: News
read moreThe approval is based on a clinical trial which showed that after an average of 30 months, the survival rate was higher in the Vyndaqel group. More: Pfizer's Vyndaqel, Vyndamax win US nod for rare disease Source: News
read moreIt’s the first substitution therapy approved in Europe to target the underlying cause of PKU by helping the body to break down Phe. More: EU approval for Palynziq in adult phenylketonuria Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals